Food and Drug Administration, HHS

§ 520.23 Acepromazine.
(a) Specifications. Each tablet contains 5, 10, or 25 milligrams (mg) acepromazine maleate.
(b) Sponsors. See No. 000010 in §510.600(c) of this chapter.
(c) Conditions of use—(1) Dogs—(i) Amount. 0.25 to 1.0 mg per pound (lb) body weight orally.
(ii) Indications for use. As an aid in tranquilization and as a preanesthetic agent.
(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(2) Cats—(i) Amount. 0.5 to 1.0 mg/lb body weight orally.
(ii) Indications for use. As a tranquilizer.
(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(75 FR 10165, Mar. 5, 2010)

§ 520.44 Acetazolamide sodium soluble powder.
(a) Specifications. The drug is in a powder form containing acetazolamide sodium, USP equivalent to 25 percent acetazolamide activity.
(b) Sponsors. See No. 053501 in §510.600(c) of this chapter.
(c) Conditions of use. (1) It is used in dogs as an aid in the treatment of mild congestive heart failure and for rapid reduction of intraocular pressure.1
(2) It is administered orally at a dosage level of 5 to 15 milligrams per pound of body weight daily.1
(3) For use only by or on the order of a licensed veterinarian.1

(40 FR 13838, Mar. 27, 1975, as amended at 67 FR 78355, Dec. 24, 2002)

§ 520.45 Albendazole oral dosage forms.

§ 520.45a Albendazole suspension.
(a) Specifications. Each milliliter of suspension contains 45.5 milligrams (mg) (4.55 percent) or 113.6 mg (11.36 percent) albendazole.
(b) Sponsor. See No. 000069 in §510.600 of this chapter.
(c) Related tolerances. See §556.34 of this chapter.
(d) Special considerations. See §500.25 of this chapter.

(40 FR 13838, Mar. 27, 1975, as amended at 67 FR 78355, Dec. 24, 2002)

§ 520.50 Tylosin.


SOURCE: 40 FR 13838, Mar. 27, 1975, unless otherwise noted.

1These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by §514.111 of this chapter, but may require bioequivalency and safety information.